Phát triển lâm sàng mới để điều trị bệnh mạch máu võng mạc

ĐIỀU NÊN rút ra từ bài viết này:

• This content is for subscribers only.
• AffaMed Therapeutics, a global clinical stage biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products, today announced that the United States Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for the clinical development of AM712 (ASKG712), a novel proprietary bispecific biologic molecule blocking both vascular endothelial….
• Đăng nhập Tham gia ngay.